UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry
Credit Suisse initiated coverage on Alkermes (NASDAQ: ALKS) with a Neutral rating and a $24.00 price target.
Credit Suisse said, "ALKS has an attractive long-term story, but we initiate at Neutral given the potential for a better entry point. Considering ALKS is up 21% YTD (Biotech up 7%, Pharma 4%), some 1H 2013 profit-taking and a potentially negative ALKS 5461 readout pose near-term risks. Conversely, a period of outperformance could start in 2H13 with our anticipated phase 3 success of aripiprazole lauroxil, a.k.a 9070 (2020 sales at $450MM; 70% probability of success). The 2014 dual chamber pen launch for Bydureon is also likely to be a positive inflection point for that franchise with positive readthrough to ALKS. At $20 the stock is more compelling given our near and long term views."
Alkermes closed at $22.19 on Wednesday.
Latest Ratings for ALKS
Date | Firm | Action | From | To |
---|---|---|---|---|
Dec 2020 | SVB Leerink | Maintains | Market Perform | |
Oct 2020 | Mizuho | Upgrades | Neutral | Buy |
Sep 2020 | B of A Securities | Maintains | Neutral |
View More Analyst Ratings for ALKS
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings